Quoin Pharmaceuticals Ltd... (QNRX)
NASDAQ: QNRX
· Real-Time Price · USD
8.52
-0.55 (-6.06%)
At close: May 30, 2025, 3:59 PM
8.53
0.12%
After-hours: May 30, 2025, 04:16 PM EDT
-6.06% (1D)
| Bid | 8.46 |
| Market Cap | 5.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.44M |
| EPS (ttm) | -34.62 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.66 |
| Analyst | Buy |
| Ask | 8.8 |
| Volume | 21,737 |
| Avg. Volume (20D) | 292,243 |
| Open | 9.00 |
| Previous Close | 9.07 |
| Day's Range | 8.44 - 9.00 |
| 52-Week Range | 5.01 - 54.95 |
| Beta | 1.60 |
About QNRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QNRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QNRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+0%
QNRX stock has given up its prior gain. Quoin Phar...
Unlock content with
Pro Subscription
1 week ago
+0%
Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.
4 months ago · accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...